biologic

Kedrab

Rabies Immune Globulin (Human)

Loss of exclusivityAugust 2029projected — 12-year biologic exclusivity estimate
CompanyKamada Ltd.View the full company profile on CliffBio

Drug detail

Brand nameKedrab
Active ingredientRabies Immune Globulin (Human)
Strength150IU/ML
Dosage formSolution
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2017
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kedrab patent cliff — loss of exclusivity August 2029 | CliffBio